OmRx Oncology begins phase 2 trial of oral PD─L1 inhibitor OX─4224 in patients with non─small cell lung cancer
OmRx Oncology, or “OmRx,” a clinical-stage biopharmaceutical venture dedicated to expanding access to cancer immunotherapy worldwide, announced the initiation of a phase 2 clinical trial of its investigational oral PD-L1 inhibitor, OX-4224, in patients …